current
PODCASTS
PODCAST (pod-cast) Definition: Stands for Personal, On-Demand, broadCAST. A short audio or video recording produced to inform or respond to
the public. Commonly, produced online, free and with the ability to subscribe.
ALS TDI is committed to creating and maintaining the most direct and open lines of communication with the ALS community. In support of this
effort, the Institute will be publishing a regular podcast on its website as well as via publishing mechanisms on iTunes. These podcasts are
audio based and last between 7-10 minutes in length, each focusing on a limited topic or number of topics. Click below to listen to recent
podcasts or subscribe to the podcast in order to receive automated notifications via RSS or iTunes when a new ALS TDI podcast is published and available.
06/01/2010 -
ALS Advocacy in Washington DC
Annie Kennedy, VP of Advocacy for the MDA and Carol Hamilton, Director of Government Affairs and Foundations at ALS TDI, discuss the current climate and activities in Washington DC to increase funding for ALS research.
04/02/2010 -
The ALS TDI Nature Genetics Paper: What does it mean?
This podcast features a conversation with Steve Perrin (CEO/CSO), John Lincecum (Director of Research Biology) and Fernando Vieira (Director of In Vivo Validation) regarding their paper published on 3/28/10 in Nature Genetics. The team talks about the immune system, the mouse model results, what the significance of the human blood sampling is, and some of the potential next steps for this potential treatment (antiCD40L or ALS TDI 00846) for ALS may be.
03/05/2010 -
Screening Potential Therapeutics in the SOD1 Mouse
Dr. Fernando Vieira, Director of In Vivo Operations ALS TDI, discusses how his team at ALS TDI, with a combined 100 years of experience in pharmacology and research, use this model of neurodegeneration, and other technologies to identify, screen and validate potential therapeutics in the battle against ALS.
02/18/2010 -
ALS Ambassadors Ted & Wendy Reich talk about Finding ALS TDI
Shortly after their son Corey was diagnosed with ALS at age 21, the Reiches met former ALS TDI president Sean Scott at an ALS Research 101 event in California. In this podcast, the couple talk about their candid relationship with Sean and their family's decision to fight Lou Gehrig's disease and raising nearly $1 million in less than two years to date.
02/01/2010 -
How is ALS TDI funded?
The Institute's VP of Development, Sally Gould, CFRE, talks about the many ways that people, corporations and foundations fund research at ALS TDI. Hrs. Gould discusses grassroots fundraising, major gifts, bequests and other mechanisms that donors use to impact the speed of ALS research.
02/01/2010 -
How far are we from an effective therapeutic for ALS?
Dr. Steve Perrin, CEO/CSO of ALS TDI provides a review of the advancements in the field over the past three years, discusses current clinical trials of high-interest to him and provides insight into what those living with ALS today can do today and how their caregivers and families can help.
02/01/2010 -
ALS TDI: A non-profit biotech
BIOtech Now's Tracy Krughoff talks with Steve Perrin, Chief Executive Officer and Chief Scientific Officer of the ALS Therapy Development
Institute, which is one of the advocacy organizations presenting at the upcoming BIO CEO & Investor Conference, being held Feb 8-9 in New York City.